Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.80 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.80 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.80 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.52 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.51 |
| ▸ | AMD1 | P17707 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28950087 | 0.91 | PI4KA (0.77) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL16256552 | 0.90 | PI4KA (0.78) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL30586379 | 0.90 | PI4KA (0.78) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL11760852 | 0.90 | PI4KA (0.65) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL8461173 | 0.90 | PI4KA (0.65) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL9225984 | 0.90 | PI4KA (0.68) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL9122399 | 0.89 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL19003199 | 0.89 | PI4KA (0.74) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL24146588 | 0.89 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL22393059 | 0.89 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024177959-A1 | SMALL MOLECULE TRACER LIGANDS FOR AMINOACYL-TRNA SYNTHETASE ASSAYS | THE GENERAL HOSPITAL CORPORATION (US) | 2024-08-29 | — | — | WO | disclosed |
| US-7989430-B2 | Antibacterial agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080293666-A1 | Antibacterial Agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-11-27 | — | — | US | disclosed |
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7084127-B2 | C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2006-08-01 | — | — | US | disclosed |
| US-6958324-B2 | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-10-25 | — | — | US | disclosed |
| US-20050203052-A1 | Inosine compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-09-15 | — | — | US | disclosed |
| US-20050014715-A1 | Inosine compounds and their use for treating or preventing an inflammation or reperfusion disease | SALZMAN ANDREW L (US) | 2005-01-20 | — | — | US | disclosed |
| EP-1469003-A2 | Tetraphosphonate bicyclic trisanhydrides | Pharmasset, Ltd. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040181078-A1 | Tetraphosphonate bicyclic trisanhydrides | PHARMASSET, LTD. | 2004-09-16 | — | — | US | disclosed |
| US-20030040502-A1 | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease | INOTEK PHARMACEUTICALS CORPORATION | 2003-02-27 | — | — | US | disclosed |
| US-20020161220-A1 | Tetraphosphonate bicyclic trisanhydrides | GILEAD PHARMASSET LLC | 2002-10-31 | — | — | US | disclosed |
| US-6326490-B1 | ANTIPROLIFERATION AGENTS OR ANTICARCINOGENIC AGENTS | PHARMASSET, LTD. | 2001-12-04 | — | — | US | disclosed |
| US-5864033-A | ENZYME INHIBITORS WITH HETEROCYCLIC BASES | METABASIS THERAPEUTICS, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5846743-A | Polyphoshoinositide binding peptides for intracellular drug delivery | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5783662-A | Polyphosphoinsitide binding peptides for intracellular drug delivery | BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1998-07-21 | — | — | US | disclosed |
| WO-1998020887-A1 | POLYPHOSPHOINOSITIDE BINDING PEPTIDES FOR INTRACELLULAR DRUG DELIVERY | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| US-5646128-A | TREATING INFLAMMATION, SEPSIS, SEPTIC SHOCK, BURNS | GENSIA, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203052-A1 | Inosine compounds and methods of use thereof | NOS2, NOS1, ARG2 | PI4KA 3067/4885PI4K2B 3234/4885PI4K2A 2981/4885 |
| US-20030040502-A1 | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease | NOS2, NOS1, ARG2 | PI4KA 3190/4885PI4K2B 3683/4885PI4K2A 3235/4885 |
| US-20050014715-A1 | Inosine compounds and their use for treating or preventing an inflammation or reperfusion disease | NOS2, NOS1, NOS3 | PI4KA 2634/4885PI4K2B 3027/4885PI4K2A 2656/4885 |
| US-20080293666-A1 | Antibacterial Agents | MRPL21, ABCB7, MSR1 | PI4KA 4490/4885PI4K2B 3867/4885PI4K2A 4444/4885 |
| US-20040181078-A1 | Tetraphosphonate bicyclic trisanhydrides | IDH1, PPIP5K2, DHPS | PI4KA 857/4885PI4K2B 1224/4885PI4K2A 917/4885 |
| US-20020161220-A1 | Tetraphosphonate bicyclic trisanhydrides | IDH1, PPIP5K2, DHPS | PI4KA 857/4885PI4K2B 1224/4885PI4K2A 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.